Erratum to: Drug Discovery vs hERG (Topics in Medicinal Chemistry, (10.1007/7355_2014_38);Drug discovery vs hERG

Topics in Medicinal Chemistry

Volumn 9, Issue , 2014, Pages 225-260

  Leishman, Derek J ^a   Rankovic, Zoran ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Herg; Medicinal chemistry; QT; Torsades de pointes

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; ASTEMIZOLE; BENZIMIDAZOLE DERIVATIVE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOFETILIDE; FEXOFENADINE; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; NEUROKININ 1 RECEPTOR ANTAGONIST; PIPERIDINE; POTASSIUM CHANNEL HERG; SEROTONIN 2A ANTAGONIST; TERFENADINE; VASCULOTROPIN INHIBITOR;

ARTICLE; CHEMICAL MODIFICATION; COMPUTER MODEL; DRUG CONTROL; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EX VIVO STUDY; HEART REPOLARIZATION; HUMAN; IC50; IN VITRO STUDY; IN VIVO STUDY; LONG QT SYNDROME; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; QT PROLONGATION; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; TORSADE DES POINTES;

EID: 84916242131     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/7355_2014_72     Document Type: Erratum

References (94)

1. Sanguinetti MC, Jurkewicz NK (1990) Two components of cardiac delayed rectifier K+ current differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96:195–215
2. Crumb WJ, Wible B, Arnold DJ, Payne JP, Brown AM (1995) Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity. Mol Pharmacol 47:181–190
3. Anonymous (1997) Committee for Proprietary Medicinal Products (CPMP). Points to consider: the assessment for the potential for QT interval prolongation by non-cardiovascular medicinal products (CPMP/986/96). European Agency for the Evaluation of Medicinal Products, London
4. Sanguinetti MC, Jiang C, Curran ME, Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81:299–307
5. Anonymous (2005) ICH harmonised tripartite guideline the non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals S7B
6. Sugiyama A (2008) Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol 154:1528–1537
7. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PKS, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32–45
8. De Bruin ML, Pettersson M, Meyboom RHB, Hoes AW, Leufkens HGM (2005) Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26:590–597
9. Allen MJ, Nichols DJ, Oliver SD (2000) The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. Br J Clin Pharmacol 50:247–253
10. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB (2000) Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 102:2385–2390
11. Bednar MM, Harrigan EP, Ruskin JN (2002) Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 89:1316–1319
12. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA (1995) HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269:92–95
13. Stansfeld PJ, Gedeck P, Gosling M, Cox B, Mitcheson JS, Sutcliffe MJ (2007) Drug block of the hERG potassium channel: insight from modeling. Proteins 68:568–580
14. London B, Trudeau MC, Newton KP, Beyer AK, Copeland NG, Gilbert DJ, Jenkins NA, Satler CA, Robertson GA (1997) Two isoforms of the mouse ether-a`-go-go–related gene coassemble to form channels with properties similar to the rapidly activating component of the cardiac delayed rectifier K+ current. Circ Res 81:870–878
15. Zehelein J, Zhang W, Koenen M, Graf M, Heinemann SH, Katus HA (2001) Molecular cloning and expression of cERG, the ether a` go-go-related gene from canine myocardium. Pflugers Arch 442:188–191
16. Hancox JC, Levi AJ, Witchel HJ (1998) Time course and voltage dependence of expressed HERG current compared with native “rapid” delayed rectifier K current during the cardiac ventricular action potential. Pflugers Arch 436:843–853
17. Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440:463–469
18. Azarbayjani F, Danielsson BR (2002) Embryonic arrhythmia by inhibition of herg channels: a common hypoxia-related teratogenic mechanism for antiepileptic drugs? Epilepsia 43:457–468
19. Bianchi L, Wible B, Arcangeli A, Tagliatatela M, Morra F, Castaido P, Crociani O, Rosati B, Faravelli L, Olivotto M, Wanke E (1998) hERG encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res 58:815–822
20. Chiesa N, Rosati B, Arcangeli A, Olivotto M, Wanke E (1997) A novel role for HERG K+ channels: spike-frequency adaptation. J Physiol 501:313–318
21. Jonker DM, Kenna LA, Leishman D, Wallis R, Milligan PA, Jonsson EN (2005) A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a`-go-go-related gene current inhibition data. Clin Pharmacol Ther 77:572–582
22. Lin C, Cvetanovic I, Ke X, Ranade V, Somberg J (2005) A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels. Am J Ther 12:328–336
23. Roden DM, Woosley RL, Primm RK (1986) Incidence and clinical features of the quinidineassociated long QT syndrome: implications for patient care. Am Heart J 111:1088–1093
24. Vereecke J, Carmeliet E (2000) The effect of external pH on the delayed rectifying K+ current in cardiac ventricular myocytes. Pflugers Arch 439:739–751
25. Anumonwo JMB, Horta J, Delmar M, Taffet SM, Jalife J (1999) Proton and zinc effects on HERG currents. Biophys J 77:282–298
26. Shrivastava IH et al (2000) Structure and dynamics of K channel pore-lining helices: a comparative simulation study. Biophys J 78:79–92
27. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC (2000) A structural basis for druginduced long QT syndrome. Proc Natl Acad Sci U S A 97:12329–12333
28. Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC (2006) HERG K+ channel blockade by the antipsychotic drug thioridazine: an obligatory role for the S6 helix residue F6Biochem Biophys Res Commun 351:273–280
29. Duncan RS, McPate MJ, Ridley JM, Gao Z, James AF, Leishman DJ, Leaney JL, Witchel HJ, Hancox JC (2007) Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol 74:425–437
30. Duncan RS, Ridley JM, Dempsey CE, Leishman DJ, Leaney JL, Hancox JC, Witchel HJ (2006) Erythromycin block of the HERG K+ channel: accessibility to F656 and Y6Biochem Biophys Res Commun 341:500–506
31. Hill AP, Sunde M, Campbell TJ, Vandenberg JI (2007) Mechanism of block of the hERG K+ channel by the scorpion toxin CnErg1. Biophys J 92:3915–3929
32. Milnes JT, Dempsey CE, Ridley JM, Crociani O, Arcangeli A, Hancox JC, Witchel HJ (2003) Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin. FEBS Lett 547:20–26
33. Zhang Y, Han H, Wang J, Wang H, Yang B, Wang Z (2003) Impairment of human ether-a`-go-go-related gene (HERG) K+ channel function by hypoglycemia and hyperglycemia: similar phenotypes but different mechanisms. J Biol Chem 278:10417–10426
34. Cockerill SL, Tobin AB, Torrecilla I, Willars GB, Standen NB, Mitcheson JS (2007) Modulation of hERG potassium currents in HEK-293 cells by protein kinase C. Evidence for direct phosphorylation of pore forming subunits. J Physiol 581:479–493
35. Marques JLB, George E, Peacey SR, Harris ND, Macdonald IA, Cochrane T, Heller SR (1997) Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med 14:648–654
36. Marfella R, Rossi F, Giugliano D (2001) Hyperglycemia and QT interval: time for re-evaluation. Diabetes Nutr Metab 14:63–65
37. Zeng H, Lozinskaya IM, Lin Z, Willette RN, Brooks DP, Xu X (2006) Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator. J Pharmacol Exp Ther 319:957–962
38. Campbell TJ (1983) Importance of physico-chemical properties in determining the kinetics of the effects of class I antiarrhythmic drugs on maximum rate of depolarization in guinea-pig ventricle. Br J Pharmacol 80:33–40
39. Zhang S, Rajamani S, Chen Y, Gong Q, Rong Y, Zhou Z, Ruoho A, January CT (2001) Cocaine blocks HERG, but not KvLQT1 + minK, potassium channels. Mol Pharmacol 59:1069–1076
40. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen X-L, Sawamura K, Reynolds W, Rampe R (2005) Pentamidine-induced long qt syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312:316–323
41. Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, Holzem KM, Delisle BP, Anson BD, Makielski JC, January CT (2006) Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149:481–489
42. Gintant GA, Su Z, Martin RL, Cox BF (2006) Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety. Toxicol Pathol 34:81–90
43. Hanson LA, Bass AS, Gintant G, Mittelstadt S, Rampe D, Thomas K (2006) ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods 54:116–129
44. Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC (2010) Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37ºC: cisapride versus dofetilide. J Pharmacol Toxicol Methods 61:178–191
45. Chiu PJS, Marcoe KF, Bounds SE, Lin C-H, Feng J-J, Lin A, Cheng FC, Crumb WJ, Mitchell R (2004) Validation of a [3H]-astemizole binding assay in HEK293 cells expressing HERG K+ channels. J Pharmacol Sci 95:311–319
46. Diaz GJ, Daniell K, Leitza ST, Martin RL, Su Z, McDermott JS, Cox BF, Gintant GA (2004) The [3H]-dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: comparison of intact cell and membrane preparations and effects of altering [K+]o. J Pharmacol Toxicol Methods 50:187–199
47. Deacon M, Singleton D, Szalkai N, Pasieczny R, Peacock C, Price D, Boyd J, Boyd H, Steidl- Nichols JV, Williams C (2007) Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade. J Pharmacol Toxicol Methods 55:255–264
48. Leishman DJ, Helliwell R, Wakerell J, Wallis RM (2000) Effects of E-4031, cisapride, terfenadine and terodiline on cardiac repolarisation in canine Purkinje fibre and HERG channels expressed in HEK293 cells. Br J Pharmacol 133:130
49. Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF (2001) The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 37:607–618
50. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF, Guinosso PJ Jr, Lynch JJ Jr (1995) Cardiac electrophysiological actions of the histamine h1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 76:110–119
51. Leishman DJ, Beck TW, Dybdal N, Gallacher DJ, Guth BD, Holbrook M, Roche B, Wallis RM (2010) Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the safety pharmacology society. J Pharmacol Toxicol Methods 65:93–101
52. Sivarajah A, Collins S, Sutton MR, Regan N, West H, Holbrook M, Edmunds N (2010) Cardiovascular safety assessments in the conscious telemetered dog: utilisation of superintervals to enhance statistical power. J Pharmacol Toxicol Methods 62:12–19
53. Webster R, Leishman D, Walker D (2002) Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 5:116–126
54. Gintant G (2011) An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 129:109–119
55. Anonymous (2000) ICH harmonised tripartite guideline safety pharmacology studies for human pharmaceuticals S7A
56. Anonymous (2005) ICH harmonised tripartite guideline the clinical evaluation of QT/QTC interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs E14
57. Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N (2014) Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the cardiac safety research consortium. Am Heart J 1–9
58. Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA (2002) Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a`-go-go-related gene potassium channel. J Pharmacol Exp Ther 301:427–434
59. Cavalli A, Poluzzi E, De Ponti F, Recanatini M (2002) Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J Med Chem 45:3844–3853
60. Cavalli A, Buonfiglio R, Ianni C, Masetti M, Luisa Ceccarini L, Caves R, Chang MWY, Mitcheson JS, Roberti M, Recanatini M (2012) Computational design and discovery of “minimally structured” hERG blockers. J Med Chem 55:4010–4014
61. Price DA, Armour D, de Groot M, Leishman D, Napier C, Perros M, Stammen BL, Wood A (2006) Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg Med Chem Lett 16:4633–4637
62. Pollard CE, Valentin J-P, Hammond TG (2008) Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br J Pharmacol 154:1538–1543
63. Jamieson C, Moir EM, Rankovic Z, Wishart G (2006) Medicinal chemistry of optimizations: highlights and hang-ups. J Med Chem 49:5029–5046
64. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6:881–890
65. Waring MJ, Johnston C (2007) A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg Med Chem Lett 17:1759–1764
66. Taboureau O, Jorgensen FS (2011) In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology. Comb Chem High Throughput Screen 14:375–387
67. Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC (2004) Physicochemical features of the hERG channel drug binding site. J Biol Chem 279:10120–10127
68. Fletcher SR, Burkamp F, Blurton P, Cheng SKF, Clarkson R, O’Connor D, Spinks D, Tudge M, van Niel MB, Patel S, Chapman K, Marwood R, Shepheard S, Bentley G, Cook GP, Bristow LJ, Castro JL, Hutson PH, MacLeod AM (2002) 4-(Phenylsulfonyl) piperidines: novel, selective, and bioavailable 5–HT2A receptor antagonists. J Med Chem 45:492–496
69. Rowley M, Hallet DJ, Goodacre S, Moyes C, Crawforth J, Sparey TJ, Patel S, Marwood R, Thomas S, Hitzel L, O’Connor D, Szeto N, Castro JL, Hutson PH, MacLeod AM (2001) 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT2A receptor antagonists. J Med Chem 44:1603–1614
70. Ritchie TR, Macdonald SJF (2009) The impact of aromatic ring count on compound developability–are too many aromatic rings a liability in drug design. Drug Discov Today 14:1011–1020
71. Hann MM, Leach AR, Harper G (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 41:856–864
72. Lovering F, Bikker J, Humblet C (2009) Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem 52:6752–6756
73. Ritchie TR, Macdonald SJF, Peace S, Pickettc SD, Luscombec CN (2013) Increasing small molecule drug developability in sub-optimal chemical space. Med Chem Commun 4:673–680
74. Blackburn C, LaMarche MJ, Brown J, Lee Che J, Cullis CA, Lai S, Maguire M, Marsilje T, Geddes B, Govek E, Kadambi V, Doherty C, Dayton B, Brodjian S, Marsh KC, Collins CA, Kym PR (2006) Identification and characterisation of amino-piperidinequinolones and quinazolinones as MCHr1 antagonists. Bioorg Med Chem Lett 16:2621–2627
75. Thoma G, Beerli C, Bigaud M, Bruns C, Cooke NG, Streiff MB, Zerwes H-G (2008) Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo. Bioorg Med Chem Lett 18:2000–2005
76. Bregman H, Nguyen HN, Feric E et al (2012) The discovery of aminopyrazines as novel, potent Nav1.7 antagonists: hit-to-lead identification and SAR. Bioorg Med Chem Lett 22:2033–2042
77. Perry M, Sanguinetti M, Mitcheson J (2010) Revealing the structural basis of action of hERG potassium channel activators and blockers. J Physiol 588:3157–3167
78. Huscroft IT, Carlson EJ, Chicchi GG, Kurtz MM, London C, Raubo P, Wheeldon A, Kulagowski JJ (2006) Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) antagonists. Bioorg Med Chem Lett 16:2008–2012
79. Sisko JT, Tucker TJ, Bilodeau MT, Buser CA, Ciecko PA, Coll KE, Fernades C, Gibbs JB, Koester TJ, Kohl N, Lynch JJ, Mao X, McLoughlin D, Miller-Stein CM, Rodman LD, Rickert KW, Sepp-Lorrenzino L, Shipman JM, Thomas KA, Wong BK, Hartman GD (2006) Potent 2-[(pyrimidin-4-yl)amine]-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase. Bioorg Med Chem Lett 16:1146–1150
80. Bhide RS, Cai ZW, Zhang YZ, Quian L, Wei D, Barbosa S, Lombardo LJ, Borzilleri RM, Zheng X, Wu LI, Barrish JC, Kim SH, Leavitt K, Mathur A, Leith L, Chao S, Wautlet B, Mortillo S, Jeyaseelan R, Kukral D, Hunt JT, Kamath A, Fura A, Vyas V, Marathe P, D’Arienzo C, Derbin G, Fargnoli J (2006) Discovery and preclinical studies of (R)-1- (4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 49:2143–2146
81. Zgu B-Y, Jia ZJ, Zhang P, Su T, Huang W, Goldman E, Tumas D, Kadambi V, Eddy P, Sinha U, Scarborough RM, Song Y (2006) Inhibitory effect of carboxylic acid group on hERG binding. Bioorg Med Chem Lett 16:5507–5512
82. Rampe D, Wibble B, Brown AM, Dage RC (1993) Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. Mol Pharmacol 44:1240–1245
83. Ghosh S, Elder A, Guo J, Mani U, Patane M, Carson K, Ye Q, Bennett R, Chi S, Jenkins T, Guan B, Kolbeck R, Smith S, Zhang C, LaRosa G, Jaffee B, Yang H, Eddy P, Lu C, Uttamsingh V, Horlick R, Harriman G, Flynn D (2006) Design, synthesis, and progress toward optimization of potent small molecule antagonists of cc chemokine receptor 8 (CCR8). J Med Chem 49:2669–2672
84. Edmondson SD, Mastracchio A, Duffy J, Eiermann GJ, He H, Ita I, Leiting B, Leone JF, Lyons KA, Makarewicz AM, Patel RA, Petrov A, Wu JK, Thornberry NA, Weber AE (2005) Discovery of potent and selective orally bioavailable β-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 15:3048–3052
85. Xu J, Mathvink R, He J, Park YJ, He H, Leiting B, Lyons KA, Marsilio F, Patel RA, Wu JK, Thornberry NA, Weber AE (2005) Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 15:2533–2536
86. Hogberg T, Frimurer TM, Sasmal PK (2012) Melanin concentrating hormone receptor 1 (MCHR1) antagonists—still a viable approach for obesity treatment? Bioorg Med Chem Lett 22:6039–6047
87. Mihalic JT, Fan P, Chen X, Chen X, Fu Y, Motani A, Liang L, Lindstrom M, Tang L, Chen J-L, Jaen J, Dai K, Li L (2012) Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition. Bioorg Med Chem Lett 22:3781–3785
88. Middleton DS, Maw GN, Challenger C, Jessiman A, Johnson PS, Million WA, Nichols CL, Price JA, Trevethick M (2006) Highly potent and selective zwitterionic agonists of the δ-opioid receptor, part 1. Bioorg Med Chem Lett 16:905–910
89. Gianotti M, Botta M, Brough S, Carletti R, Castiglioni E, Corti C, Dal-Cin M, Fratte SD, Korajac D, Lovric M, Merlo G, Mesic M, Pavone F, Piccoli L, Rast S, Roscic M, Sava A, Smehil M, Stasi L, Togninelli A, Wigglesworth M (2010) Novel Spirotetracyclic Zwitterionic Dual H1/5-HT2A receptor antagonists for the treatment of sleep disorders. J Med Chem 53:7778–7795
90. Sullivan S, Guilleminault C (2009) Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin Emerg Drugs 14:411–422
91. McCauley JA, Theberge CR, Romano JJ, Billings SB, Anderson KD, Claremon DA, Freidinger RM, Bednar RA, Mosser SD, Gaul SL, Connolly TM, Condra CL, Xia M, Cunningham ME, Bednar B, Stump GL, Lynch JJ, Macaulay A, Wafford KA, Koblan KS, Liverton NJ (2004) NR2B-selective N-Methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem 47:2089–2096
92. Shu M, Loebach JL, Parker KA, Mills SG, Chapman KT, Shen DM, Malkowitz L, Gould SL, DeMartino JA, Siciliano SJ, DiSalvo J, Lyons K, Pivnichny JV, Kwei GY, Carella A, Carver G, Holmes K, Schleif WA, Danezeisen R, Hazuda D, Kessler J, Lineberger J, Miller MD, Emini EA (2004) Antagonists of the human CCR5 receptor containing 4-(pyrazolyl) piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment. Bioorg Med Chem Lett 14:947–952
93. Bell IM, Gallicchio SN, Abrams M, Beshore DC, Buser CA, Culberson JC, Davide J, Ellis- Hutchings N, Fernandes C, Gibbs JB, Graham SL, Hartman GD, Heimbrook DC, Homnick CF, Huff JR, Hassahun K, Koblan KS, Kohl NE, Lobell RB, Lynch JJ, Miller PA, Omer CA, Rodrigues AD, Walsh ES, Williams TM (2001) Design and biological activity of (S)-4- (5-{[1-(3-Chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency. J Med Chem 44:2933–2949
94. Kang J, Reynolds WP, Chen XL, Ji J, Wang H, Rampe DE (2006) Mechanisms underlying the QT interval–prolonging effects of sevoflurane and its interactions with other QT-prolonging drugs. Anesthesiology 104:1015–1022